Treatment of Metastatic Non-Small Cell Lung Cancer
Chemotherapy in combination with bevacizumab is the current standard for the first-line treatment of metastatic NSCLC for patients without contraindications.
Women obtain equal benefit from the addition of bevacizumab to chemotherapy for NSCLC as men.
A significant part of the mechanism of the antitumor action of bevacizumab in NSCLC is improved delivery of chemotherapy to the tumor.
When using a taxane-based regimen in the metastatic setting, what percent of the time do you use the following agents? (Mean)
Which doublet chemotherapy regimen is your usual first choice for a patient with metastatic NSCLC and a good performance status?
A 60-year-old man with a history of smoking and a performance status of 1 presents with metastatic adenocarcinoma of the lung with bone and adrenal involvement. In this setting, how would you compare cisplatin/docetaxel (CisDoce) to cisplatin/vinorelbine (CisVin)?
A 60-year-old man with a history of smoking and a performance status of 1 presents with metastatic adenocarcinoma of the lung with bone and adrenal involvement. In this setting, how would you compare cisplatin/docetaxel (CisDoce) to cisplatin/vinorelbine (CisVin)?
The following are predisposing risk factors for hemoptysis in patients with NSCLC receiving bevacizumab.
The following are predisposing risk factors for hemoptysis in patients with NSCLC receiving bevacizumab.
Which of the following do you consider the most important predisposing risk factor for hemoptysis in patients with NSCLC receiving bevacizumab?*
What is your feeling regarding the use of bevacizumab outside of a protocol setting in each of the following scenarios?
What is your feeling regarding the use of bevacizumab outside of a protocol setting in each of the following scenarios?
Have you used bevacizumab for patients receiving therapeutic anticoagulation?*
A 65-year-old patient with a history of smoking and a good performance status presents with adenocarcinoma of the lung that has metastasized to the bone and liver. In this setting, how would you compare carboplatin/paclitaxel (CarboPac) to CarboPac and bevacizumab (CarboPacBev)?
A 65-year-old patient with a history of smoking and a good performance status presents with adenocarcinoma of the lung that has metastasized to the bone and liver. In this setting, how would you compare carboplatin/paclitaxel (CarboPac) to CarboPac and bevacizumab (CarboPacBev)?
A 65-year-old patient with a history of smoking and a good performance status presents with adenocarcinoma of the lung that has metastasized to the bone and liver. In this setting, how would you compare cisplatin/gemcitabine (CisGem) to CisGem and bevacizumab (CisGemBev)?
A 65-year-old patient with a history of smoking and a good performance status presents with adenocarcinoma of the lung that has metastasized to the bone and liver. In this setting, how would you compare cisplatin/gemcitabine (CisGem) to CisGem and bevacizumab (CisGemBev)?
Have you ordered the EGFR mutation test for a patient with NSCLC
Patient gender plays a role in my decision to utilize erlotinib in the second-line management of advanced NSCLC.
A 62-year-old female nonsmoker presents with recurrent NSCLC with mediastinal node involvement and distant metastases to the bone and adrenal gland. She previously received adjuvant carboplatin/paclitaxel and is 2 years from original diagnosis. Erlotinib should be administered as part of her first-line treatment.
Which of the following best represents the way you utilize erlotinib in metastatic disease?*
A 60-year-old female nonsmoker presents with metastatic NSCLC with asymptomatic bone involvement and mutated EGFR status. In this setting, how would you compare first-line erlotinib to carboplatin/paclitaxel (CarboPac)?
A 60-year-old female nonsmoker presents with metastatic NSCLC with asymptomatic bone involvement and mutated EGFR status. In this setting, how would you compare first-line erlotinib to carboplatin/paclitaxel (CarboPac)?
A 60-year-old female nonsmoker presents with metastatic NSCLC with asymptomatic bone involvement and mutated EGFR status. In this setting, how would you compare first-line erlotinib to carboplatin/paclitaxel (CarboPac)?
A female nonsmoker presents with de novo metastatic, pure bronchoalveolar carcinoma with bone and adrenal involvement. She has a good performance status and good renal function and wants to be aggressive with treatment. Which treatment would you most likely recommend if the patient was:
A female nonsmoker presents with de novo metastatic, pure bronchoalveolar carcinoma with bone and adrenal involvement. She has a good performance status and good renal function and wants to be aggressive with treatment. Which treatment would you most likely recommend if the patient was:
What would be your most likely recommendation for a patient with de novo metastatic NSCLC if the patient was:
What would be your most likely recommendation for a patient with de novo metastatic NSCLC if the patient was:
For patients who demonstrate stable disease after 6 cycles of chemotherapy with bevacizumab, I continue bevacizumab as maintenance therapy.
A patient with Stage IV NSCLC and a good performance status who has stable disease following 4 cycles of carboplatin/ gemcitabine chemotherapy should receive maintenance docetaxel chemotherapy.
A 60-year-old patient has an excellent response to carboplatin/paclitaxel/
bevacizumab as first-line therapy for metastatic disease and is continued on bevacizumab. At 16 months, the patient develops slow but definite disease progression. Outside a protocol setting, the following patients should be offered which treatment?
A 60-year-old patient has an excellent response to carboplatin/paclitaxel/
bevacizumab as first-line therapy for metastatic disease and is continued on bevacizumab. At 16 months, the patient develops slow but definite disease progression. Outside a protocol setting, the following patients should be offered which treatment?
